Citation | Country | Triptans (forms) | n | PS (%) | Time point for DCS, WCS, and BCS | DC (%) | WCS (%) | BCS (% of total cohort) | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Overall | Opioid | NSAIDsab | BAR | Ergots | ||||||||
Chen, 2014 [36] | Taiwan | suma, riza (oral, sc) | 13,951 | 4.0 by 2-yrs | 1st refill | 24.8 | 0.01 | 40.9 | 1.2 | 18.8 | 0 | 11.3 |
Fischer, 2016 [37] | Austria | ele, frova, suma, zolmi (NR) | 126 | NR | 1st follow-up visit | 10.8 | 15.1 | 14.6a | NAa | 14.6ab | NR | NR |
Katic, 2011 [38] | US | almo, nara, ele, frova, suma, riza, zolmi (all) | 40,892 | 6.4 by 2-yrs | 1st refill | 13.7 | 4.0 | 36.2 | 18.2 | 12.5 | 2.6 | 0 |
Lombard, 2018 [39]c | US | NR | 124,556 | 15.0 by 1-yr | with one change after 1-year | 22.5 | 3.2 | 29.1 | 15.5 | 11.6a | 1.9 | NR |
Ng-Mak, 2012 [40] | UK | almo, ele, frova, nara, riza, suma, zolmi (oral) | 3618 | 13.0 by 2-yr | 1st refill | 48.5 | 4.9 | 2.3 | 0.1 | 0.9 | 0 | 0.2 |
France | 2051 | 6.0 by 2-yr | 1st refill | 54.9 | 6.8 | 4.0 | 0 | 2 | 0 | 0.6 | ||
Germany | 954 | 9.0 by 2-yr | 1st refill | 54.7 | 6.3 | 2.3 | 0 | 1.3 | 0 | 0.1 |